Under the title, What’s Next in Psoriasis? From Maintenance to Disease Modification, the 2022 IPC Think Tank scientific symposium was held on Friday, December 9th, in Miami, Florida. Read the full report or a summary of the five psoriasis focused sessions.
Recently, a study was conducted on the effect of apremilast on vascular inflammation and cardiometabolic functions with an impressively comprehensive set of markers for vascular inflammation and cardiometabolic disease. Peter van de Kerkhof, MD, PhD, provides his expert opinion on the overall conclusion and the implications of this study are discussed.
The International Psoriasis Council (IPC) and Scientific Education Support (SES) are excited to announce a strategic collaboration aimed to improve awareness, knowledge, and understanding of psoriasis, psoriatic arthritis, and other related diseases.
The European Academy of Dermatology and Venereology (EADV) organized its 31st congress in Milano, Italy, under the parole “Designing the Future of Dermatology and Venereology.” The event took place from September 7 – 10, 2022, as a hybrid meeting with the option of attending virtually or in person. The following congress report includes fifteen summaries of presentations focusing on psoriasis. You can download the full report or read the summary.
The Global Psoriasis Atlas (GPA) is a joint project of the ILDS (International League of Dermatological Societies), IFPA (International Federation of Psoriasis Associations), and IPC (International Psoriasis Council) delivered by staff based at the University of Manchester. Its goal is to provide the benchmark on the burden of psoriasis in all countries and regions throughout the world using comprehensive epidemiological data to inform research, policy, and healthcare.
The United States Food and Drug Administration (FDA) has approved deucravacitinib to treat psoriasis. Recently, 52-week efficacy and safety data of deucravacitinib were compared and contrasted with placebo and apremilast. The outcome of this comparative study lends support for the position of deucravacitinib in the spectrum of treatments for psoriasis.
Researchers at Cardiff University have created and launched The Official DLQI App, designed to measure the quality of life for people with skin conditions. The app is free to download in the Apple and Android stores and is now available in seven languages!
Annually, the IPC Board selects a specific subject of importance and commissions a group of experts to conduct a best evidence review. In 2021, IPC supported the BIOMAP collaboration to complete a systematic review on biomarkers. Last month, two new lay summaries were published by BIOMAP on this project.
The Society of Investigative Dermatology (SID) Annual Meeting returned to an in-person format in 2022 for the first time in two years. The following congress report includes a summary of the Eugene Farber lecture, three IPC lectures, and seven IPC poster presentations, all with a focus on psoriasis. You can download the full report or read on for a brief look at some of the highlights.
The Society of Investigative Dermatology (SID) Annual Meeting returned to an in-person format in 2022 for the first time in two years. The following congress report includes a summary of the Eugene Farber lecture, three IPC lectures, and seven IPC poster presentations, all with a focus on psoriasis. You can download the full report or read on for a brief look at some of the highlights.
PsoProtect, a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis, has updated their preliminary data and now includes the first 1,652 cases.
Amgen presents new data on the efficacy of apremilast in patients with mild to moderate plaque psoriasis and in patients with palmoplantar pustulosis.
